PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29596834-8	2018	BRD4-regulated proteins, including c-Myc, Bcl-2 and cyclin D1, were significantly downregulated following AZD5153 treatment in TPC-1 and primary cancer cells.	AZD5153	106-113	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	35-40	
31523195-11	2019	Western blotting showed that AZD5153 inhibited the expression of c-Myc and increased expression of the apoptosis markers, cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP), besides, we found that BRD4 knockdown could also inhibited cell proliferation and induced cell apoptosis.	AZD5153	29-36	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	65-70	
29931583-6	2019	At the molecular level, AZD5153 was potent in downregulating various molecules for oncogenesis, such as c-MYC, AKT2 and MAP3K; those involved in the BCR signaling pathway, such as CD19, BLNK and CD79B; and those associated with B-cell development, such as IKZF1, IKZF3, PAX5, POU2AF1 and EBF1.	AZD5153	24-31	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109	
29596834-10	2018	BRD4-dependent proteins, Myc, Bcl-2 and cyclin D1, were also downregulated in AZD5153-treated tumor tissues.	AZD5153	78-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	25-28	
27573426-8	2016	AZD5153 treatment markedly affects transcriptional programs of MYC, E2F, and mTOR.	AZD5153	0-7	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-66	
27573426-10	2016	Transcriptional modulation of MYC and HEXIM1 was confirmed in AZD5153-treated human whole blood, thus supporting their use as clinical pharmacodynamic biomarkers.	AZD5153	62-69	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	30-33